DIN 02479613 — AIMOVIG 70 MG
AIMOVIG is a solution of Erenumab marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Erenumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02479613
- Brand name
- AIMOVIG
- Active ingredient
- Erenumab
- Strength
- 70 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Calcitonin gene-related peptide receptor (CGRP-R) antagonist (monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Erenumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02487306 | AIMOVIG | 140 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |